PT92123A - Processo para a preparacao de composicoes para controlar a hipertensao ocular com esteroides angiostaticos - Google Patents

Processo para a preparacao de composicoes para controlar a hipertensao ocular com esteroides angiostaticos

Info

Publication number
PT92123A
PT92123A PT92123A PT9212389A PT92123A PT 92123 A PT92123 A PT 92123A PT 92123 A PT92123 A PT 92123A PT 9212389 A PT9212389 A PT 9212389A PT 92123 A PT92123 A PT 92123A
Authority
PT
Portugal
Prior art keywords
ocular hypertension
compositions
preparation
angiostatic steroids
controlling
Prior art date
Application number
PT92123A
Other languages
English (en)
Other versions
PT92123B (pt
Inventor
Abbot F Clark
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Publication of PT92123A publication Critical patent/PT92123A/pt
Publication of PT92123B publication Critical patent/PT92123B/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0027—Azides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
PT92123A 1988-10-31 1989-10-27 Processo para a preparacao de composicoes para controlar a hipertensao ocular com esteroides angiostaticos PT92123B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/264,918 US4876250A (en) 1988-10-31 1988-10-31 Methods for controlling ocular hypertension with angiostatic steroids

Publications (2)

Publication Number Publication Date
PT92123A true PT92123A (pt) 1990-05-31
PT92123B PT92123B (pt) 1995-06-30

Family

ID=23008183

Family Applications (1)

Application Number Title Priority Date Filing Date
PT92123A PT92123B (pt) 1988-10-31 1989-10-27 Processo para a preparacao de composicoes para controlar a hipertensao ocular com esteroides angiostaticos

Country Status (11)

Country Link
US (1) US4876250A (pt)
EP (1) EP0371617B1 (pt)
JP (1) JP3049504B2 (pt)
KR (1) KR900005984A (pt)
AT (1) ATE106731T1 (pt)
AU (1) AU628874B2 (pt)
CA (1) CA2001936C (pt)
DE (1) DE68915958T2 (pt)
DK (1) DK172058B1 (pt)
NZ (1) NZ231086A (pt)
PT (1) PT92123B (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407926A (en) * 1987-12-29 1995-04-18 Alcon Laboratories, Inc. Ophthalmic composition
US5990099A (en) * 1988-10-31 1999-11-23 Alcon Laboratories, Inc. Angiostatic agents and methods and compositions for controlling ocular hypertension
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
US5209926A (en) * 1990-06-12 1993-05-11 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5256408A (en) * 1990-06-12 1993-10-26 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5252319A (en) * 1990-06-12 1993-10-12 Insite Vision Incorporated Aminosteroids for ophthalmic use
CA2105378A1 (en) * 1991-03-21 1992-09-22 Paolo A. Paciucci Compositions and methods of treatment of a variety of disorders utilizing etianate and agonists thereof
US5239094A (en) * 1991-04-12 1993-08-24 Brigham And Women's Hospital Tetrahydro-S-21-Br
ES2139602T3 (es) * 1991-06-18 2000-02-16 Theramex Composiciones oculares que contienen esteroides y su utilizacion para el tratamiento del glaucoma.
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5679666A (en) * 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
EP1236471A3 (en) * 1991-11-22 2004-12-15 Alcon Laboratories, Inc. Angiostatic steroids
US5474985A (en) * 1993-12-22 1995-12-12 The Regents Of The University Of California Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors
US5646136A (en) * 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
US5521168A (en) * 1994-10-13 1996-05-28 Alcon Laboratories, Inc. Estrogen metabolites for lowering intraocular pressure
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
US5599535A (en) * 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
US6172054B1 (en) 1995-06-15 2001-01-09 Alcon Laboratories, Inc. Combination therapy for lowering and controlling intraocular pressure
EP1057486A1 (en) * 1995-11-17 2000-12-06 Alcon Laboratories, Inc. Use of drug combination for treating Glaucoma
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
AU1935501A (en) * 1999-12-09 2001-06-18 Alcon Universal Limited Id protein inhibitors for treating ocular diseases
US8679089B2 (en) * 2001-05-21 2014-03-25 Michael S. Berlin Glaucoma surgery methods and systems
US9603741B2 (en) 2000-05-19 2017-03-28 Michael S. Berlin Delivery system and method of use for the eye
DE60131273T2 (de) 2000-05-19 2008-08-28 Michael S. Beverly Hills Berlin Laserapplikationssystem und methode zur verwendung im auge
EP1341541A4 (en) * 2000-11-16 2004-11-17 Alcon Mfg Ltd COMBINATION THERAPY FOR LOWERING AND CONTROLLING THE EYE PRESSURE
CN1684701B (zh) * 2002-07-30 2012-10-17 奥默罗斯公司 眼科冲洗液及方法
CA2494211A1 (en) * 2002-08-05 2004-02-12 Alcon, Inc. Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
JP2007506678A (ja) * 2003-09-23 2007-03-22 アルコン，インコーポレイテッド 注入のためのトリアムシノロンアセトアニドおよび酢酸アネコルタブの処方物
US20170360609A9 (en) 2007-09-24 2017-12-21 Ivantis, Inc. Methods and devices for increasing aqueous humor outflow
US8267882B2 (en) 2008-03-05 2012-09-18 Ivantis, Inc. Methods and apparatus for treating glaucoma
ES2548138T3 (es) 2008-05-28 2015-10-14 Reveragen Biopharma, Inc. Moduladores esteroideos no hormonales de NF-kappaB para el tratamiento de enfermedades
JP5635605B2 (ja) 2009-07-09 2014-12-03 イバンティス インコーポレイテッド 眼内インプラント及び眼内インプラントを眼球内に送出するための方法
CN102481171B (zh) 2009-07-09 2015-01-28 伊万提斯公司 用于输送眼部植入物的单人操作装置
WO2011127048A2 (en) 2010-04-05 2011-10-13 Validus Biopharma NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE
US20120283557A1 (en) 2011-05-05 2012-11-08 Berlin Michael S Methods and Apparatuses for the Treatment of Glaucoma using visible and infrared ultrashort laser pulses
US8657776B2 (en) 2011-06-14 2014-02-25 Ivantis, Inc. Ocular implants for delivery into the eye
US8663150B2 (en) 2011-12-19 2014-03-04 Ivantis, Inc. Delivering ocular implants into the eye
US9358156B2 (en) 2012-04-18 2016-06-07 Invantis, Inc. Ocular implants for delivery into an anterior chamber of the eye
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
US10617558B2 (en) 2012-11-28 2020-04-14 Ivantis, Inc. Apparatus for delivering ocular implants into an anterior chamber of the eye
WO2016011056A1 (en) 2014-07-14 2016-01-21 Ivantis, Inc. Ocular implant delivery system and method
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
US10799514B2 (en) 2015-06-29 2020-10-13 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
JP6837475B2 (ja) 2015-08-14 2021-03-03 イバンティス インコーポレイテッド 圧力センサを備えた眼用インプラントおよび送達システム
US11938058B2 (en) 2015-12-15 2024-03-26 Alcon Inc. Ocular implant and delivery system
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
US11540940B2 (en) 2021-01-11 2023-01-03 Alcon Inc. Systems and methods for viscoelastic delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617299A (en) * 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
EP0197158B1 (en) * 1984-10-05 1993-01-13 Olympus Optical Co., Ltd. Compound magnetic head
EP0245357B1 (en) * 1985-10-23 1991-08-07 The Upjohn Company Angiostatic steroids
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
US4863912A (en) * 1986-05-19 1989-09-05 New York Medical College Use of tetrahydrocortisol in glaucoma therapy
US4945089A (en) * 1987-12-29 1990-07-31 Alcon Laboratories, Inc. Use of tetrahydrocortexolone to prevent elevations in intraocular pressure caused by corticosteroids

Also Published As

Publication number Publication date
DK542989D0 (da) 1989-10-31
EP0371617A3 (en) 1992-01-22
AU4370289A (en) 1990-05-03
JPH02196722A (ja) 1990-08-03
PT92123B (pt) 1995-06-30
NZ231086A (en) 1991-07-26
DE68915958T2 (de) 1994-09-22
CA2001936C (en) 2000-04-25
AU628874B2 (en) 1992-09-24
EP0371617B1 (en) 1994-06-08
US4876250A (en) 1989-10-24
JP3049504B2 (ja) 2000-06-05
EP0371617A2 (en) 1990-06-06
DE68915958D1 (de) 1994-07-14
DK542989A (da) 1990-05-01
CA2001936A1 (en) 1990-04-30
KR900005984A (ko) 1990-05-07
ATE106731T1 (de) 1994-06-15
DK172058B1 (da) 1997-10-06

Similar Documents

Publication Publication Date Title
PT92123A (pt) Processo para a preparacao de composicoes para controlar a hipertensao ocular com esteroides angiostaticos
DK0614463T3 (da) Angiostatiske steroider
DK1920764T4 (da) Fluprostenolisopropylester til anvendelse ved behandling af glaukom og okulær hypertension
ES2193901T1 (es) Derivados de prostaglandina para el tratamiento de glaucoma o hipertension ocular.
MX9702349A (es) Usos de derivado de 9-deoxi prostaglandina para tratar glaucoma.
CA2315829A1 (en) Angiostatic agents and compositions for controlling ocular hypertension
AU7317387A (en) Use of tetrahydrocortisol in glaucoma therapy
AU3693789A (en) New ophthalmic preparation for treating glaucoma
MX24839A (es) 3-arilcarbonil-1-aminoalquilo-1h-indoles, proceso para su preparacion y composicion farmaceutica quelos contiene.
WO1998039293A3 (en) 13-thia prostaglandins for use in glaucoma therapy
AU687906B2 (en) Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
DE69106777D1 (de) Behandlung von intraokularem Druck mit einer ophthalmischen synergistischen Kombination.
ATE204752T1 (de) Therapeutische anwendungen von 2',5'- oligoadenylat-derivaten
ES2171233T3 (es) Uso de eliprodil para la preparacion de un medicamento para el tratamiento de trastornos isquemicos de la retina o el nervio optico.
ES2059058T3 (es) Combinacion sinergica para uso oftalmico.
ES2043896T3 (es) Procedimiento para la preparacion de derivados de tetrahidropiridina.

Legal Events

Date Code Title Description
MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20091205